Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2013 16:15 ET | Source: Zogenix

Zogenix Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
December 17, 2013 08:30 ET | Source: Zogenix

Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team

SAN DIEGO, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
December 11, 2013 07:30 ET | Source: Zogenix

Zogenix Reports Granting of Inducement Awards

SAN DIEGO, Dec. 11, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
December 10, 2013 08:30 ET | Source: Zogenix

Zogenix Announces FDA Approval of 4 mg SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-Free Delivery System

SAN DIEGO, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders...
December 04, 2013 07:30 ET | Source: Zogenix

Zogenix to Present at the Oppenheimer 24th Annual Healthcare Conference

SAN DIEGO, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system...
December 03, 2013 07:30 ET | Source: Zogenix

Zogenix and Battelle Expand DosePro Technology Business Agreement

SAN DIEGO and COLUMBUS, Ohio, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle today announced that they have entered into a new long-term collaborative agreement regarding...
November 12, 2013 16:30 ET | Source: Zogenix

Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters

SAN DIEGO, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
November 05, 2013 19:50 ET | Source: Zogenix

Zogenix Prices Public Offering of Common Stock

SAN DIEGO, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
November 04, 2013 06:51 ET | Source: Zogenix

Zogenix Announces Proposed Public Offering of Common Stock

SAN DIEGO, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
November 04, 2013 06:00 ET | Source: Zogenix

Zogenix Reports Third Quarter 2013 Financial Results

Business Highlights and Milestones Received FDA Approval for Zohydro™ ER (hydrocodone bitartrate), an extended-release oral formulation of hydrocodone without acetaminophen Announced...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right